Skip to main content

Founded with a $100 million gift dedicated to supporting breakthrough ideas that transform patient care, the Institute funds cutting-edge innovations and seeks to move assets from discovery to early development studies.  In addition to funding, the Institute provides critical infrastructure and milestone-driven project management of assets.  Our portfolio is made up of early-stage therapeutics assets and technology platforms in oncology, neuroscience, pulmonary, and infectious disease. Our de-risking activities go beyond the typical academic translational models to yield more viable assets for downstream commercial partners, and we actively seek strategic partners to advance our therapeutics pipeline.